Exon skipping has been demonstrated to be a successful strategy for the gene therapy of Duchenne muscular dystrophy (DMD): the rational being to convert severe Duchenne forms into milder Becker ones. Here, we show the selection of U1 snRNA-antisense constructs able to confer effective rescue of dystrophin synthesis in a Δ44 Duchenne genetic background, through skipping of exon 45; moreover, we demonstrate that the resulting dystrophin is able to recover timing of myogenic marker expression, to relocalize neuronal nitric oxide synthase (nNOS) and to rescue expression of miRNAs previously shown to be sensitive to the Dystrophin-nNOS-HDAC2 pathway. Becker mutations display different phenotypes, likely depending on whether the shorter protein is able to reconstitute the wide range of wild-type functions. Among them, efficient assembly of the dystrophinassociated protein complex (DAPC) and nNOS localization are important. Comparing different Becker deletions we demonstrate the correlation between the ability of the mutant dystrophin to relocalize nNOS and the expression levels of two miRNAs, miR-1 and miR29c, known to be involved in muscle homeostasis and to be controlled by the Dys-nNOS-HDAC2 pathway.
IntroductIon
Duchenne muscular dystrophy (DMD) is a rare disorder due to mutations in the dystrophin gene, the largest human gene, made of 79 exons alternatively arranged in tissue-specific isoforms. 1 In skeletal muscles, dystrophin is localized on the inner face of the sarcolemma, where it interacts with a complex of proteins named dystrophin-associated protein complex (DAPC). 2 In the absence of dystrophin, the DAPC complex is destabilized and muscle fibres become more sensitive to mechanical damage leading to muscle degeneration, chronic inflammation, susceptibility to oxidative stress and increased fibrosis. Besides organization of the DAPC, dystrophin was described to be important also for the localization of the neuronal nitric oxide synthase (nNOS). Specific dystrophin domains were described to be required for this activity [3] [4] [5] which also involves syntrophin interaction. 6, 7 Delocalization of nNOS was shown to impair nitric oxide (NO) production in dystrophic muscles. 8 The relevance of this pathway on muscle pathology was demonstrated by the fact that rescue of nNOS expression in mdx animals prevented exercise-related fatigue 9 and ameliorated the dystrophic phenotype. 10, 11 In addition NO has recently emerged as a key player in mediating epigenetic changes during neuronal development by repressing histone deacetylase 2 (HDAC2) activity through S-nitrosylation. 12 Along this line, in the dystrophindeficient mdx mice, defective for the NO-pathway, the activity of HDAC2 resulted to be specifically increased 13 and deacetylase inhibitors were shown to confer a strong morphofunctional benefit to dystrophic muscle fibres.
14 Finally, lower HDAC2 nitrosylation state in Duchenne versus healthy conditions was shown to reduce the expression of a specific subset of microRNAs with a relevant role in muscle differentiation and homeostasis. 15 Therefore, these data indicate that dystrophin is able to control gene expression through nNOS localization and NO-mediated HDAC2 activity (DYS-nNOS pathway). This feature should be considered when planning dystrophin rescue of different DMD mutations.
The majority of Duchenne mutations are substitutions, deletions and duplications leading to frame shift and premature translation termination. 16 On the contrary, if mutations do not perturb the reading frame, shorter and partially functional proteins are produced giving rise to the Becker muscular dystrophy (BMD) phenotype. BMD patients with large deletions can show very mild symptoms 17, 18 when spectrin-like repeat domains are involved; on the contrary rare in frame deletions that affect crucial domains for dystrophin function result in severe DMD-like phenotypes. 3 BMD-like molecules associated with the mildest phenotypes are those in which nNOS is efficiently retained at the sarcolemma. 19 For these reasons exon skipping, which is based on the principle of [24] [25] [26] [27] , or as part of a small nuclear RNA (snRNA), which provide persistent expression, in vivo stability and correct cellular compartmentalization.
28 U1 and U7 snRNA-derived antisense molecules have been shown to be effective in inducing exon skipping both in human DMD myoblasts [28] [29] [30] [31] and in the mdx mouse [32] [33] [34] [35] where a life-long beneficial effect was obtained 36 together with recovery of serum biomarkers diagnostic of muscle damage. 37 In this article, we tested in a DMD Δ44 genetic background, different U1 snRNA-antisense sequences for the ability to induce exon 45 skipping and recovery of dystrophin. According to several large databases (Leiden muscular dystrophy database; http://www.dmd. nl; UMD-DMD France mutations database 38 ) skipping of this exon should be applicable to ~8% of all known DMD mutations. 39 Eight different antisense constructs were tested for exon 45 skipping activity in lentiviral-transduced Δ44 human DMD myoblasts. Several effective molecules were obtained that produced dystrophin rescue and nNOS relocalization to the membrane. Moreover, following in vitro myoblasts differentiation, exon skipping achieved restoration of the timing of myogenic markers expression towards control levels. Notably, miRNAs previously shown to depend on the DYS-nNOS pathway were also recovered in their expression. Finally, the analysis of biopsies from BMD patients with different mutations confirmed the correlation between the ability of dystrophin to relocalize nNOS and the expression of several molecular markers linked to the DYS-nNOS pathway. #2   #3   #4   #5   #6   #7   #8   #1  #2  #3  #4  #5  #6  #7  #8   #1  #2  #3  #4  #5  #6  PGK  #7  #8  CTRL   #1  #2  #3  #4  #5  #6  PGK  #7  #8   #1  #2  #3  #4  #5  #6  PGK  #7 rEsults design and expression analysis of antisense molecules against exon 45 of the dystrophin gene Eight constructs, in the backbone of the U1 snRNA, were designed and produced for the skipping of exon 45 of the dystrophin premRNA (Figure 1a) . Nucleotides from position 3 to 10 at the 5′ end of U1 snRNA, required for the recognition of 5′ splice sites 40 were substituted with antisense sequences complementary to different portions of exon 45 and splice sites (Supplementary Table S1 ). The initial construct (#1) contained antisense sequences against both splice junctions since we previously showed that both splice sites have to be targeted in order to induce efficient exon skipping when using U1 snRNA. 28 Additional constructs were produced that contained also antisense sequences against putative ESEs, known to represent effective target substrates for efficient exon skipping. 21, 41, 42 The chimeric U1-antisense sequences were cloned under the control of the strong polII U1 snRNA gene promoter and termination sequences, and subsequently inserted in the dU3 portion of the 3′ long-terminal repeat region of a lentiviral vector plasmid. 43 The expression and stability of the different constructs were tested by transfection into the murine myogenic C 2 7 cell line. The relative expression was measured by co-transfection with the U16-RBE plasmid 44 and normalized for the endogenous U2 snRNA. Northern blot analysis indicated that all chimeric molecules accumulated at fairly similar levels (Figure 1b) . study of exon skipping activity in human dMd myoblasts Lentiviral particles for each construct were produced in 293T cells and used to transduce DMD myoblasts carrying the deletion of exon 44 (Δ44, provided by the Telethon Neuromuscular Biobank). In this case, skipping of exon 45 allows restoration of the correct reading frame and the production of a dystrophin protein 106 aminoacids shorter than the wild type. Δ44 cells were infected with comparable amounts of the different recombinant lentiviruses. After infection, they were induced to differentiate and samples were collected after 10 days for RNA and protein analysis. Exon Myosin heavy chain (MHC) detection was used as a marker of muscle terminal differentiation. This analysis revealed that constructs #6 and #8, targeting only the 3′ splice junction and ESE sequences, are poorly active in terms of dystrophin recovery. Moreover, #1, targeting the two splice junctions, provided very low skipping activity and dystrophin rescue. The importance of the simultaneous targeting of splice sites and ESE is shown by constructs #3 and #4 that provided the highest rescue of dystrophin synthesis (see the histogram of Figure 1d ). Interestingly to note that higher levels of dystrophin correlated with increase in the MHC terminal differentiation marker (Figure 1d , panel MHC).
dystrophin levels affect myogenic differentiation
In vitro cultured DMD myoblasts display a delay in the appearance of typical myogenic markers; 45 this can be easily appreciated when comparing in vitro differentiation of Δ44 myoblasts with control ones derived from a healthy individual: Figure 2a shows that the terminal differentiation marker MHC, already present at day 6 of differentiation in control cells, is poorly detectable in Δ44 cells even at day 10. Notably, when exon skipping was applied, the treated DMD myoblasts showed an effective recovery of the timing of myogenic marker appearance: Figure 2b shows a time course (3, 6 , and 10 days of differentiation) on mock infected (Δ44-PGK) and exon-skipping treated (Δ44#4) Δ44 cells. Dystrophin rescue in treated cells was paralleled by a relevant temporal restoration of late/terminal differentiation markers; in particular, MHC appeared at day 6 similarly to control cells, even if at lower levels, and muscle creatine kinase (MCK) at day 3. A direct comparison on the same gel of MHC and MCK expression levels in healthy control (CTRL), Δ44 (Δ44), mock-infected Δ44 (Δ44-PGK), and exon-skipping treated Δ44 (Δ44#4) at latest time points (6 and 10 days after shift to differentiation medium) is shown in Supplementary Figure  S1a . These results clearly demonstrate that, with respect to healthy myoblasts, the delay of appearance of late myogenic markers (MHC and MCK) in untreated (Δ44) and mock infected (Δ44-PGK) DMD cells is recovered in exon-skipping treated (Δ44#4) cells. Moreover, immunostaining analysis of Figure 2c (and more examples in Supplementary Figure S1b) indicates that the terminal differentiation marker MHC, already present at day 8 of differentiation in control cells (CTRL), is almost undetectable in mock infected Δ44 cells (Δ44-PGK) at day 12. At this time point, efficient recovery of MHC staining was detected when exon skipping was applied (Δ44#4).
To further analyze the link between dystrophin expression and muscle differentiation, RNA interference against dystrophin was performed on human myoblasts from a healthy control. siRNAs were transfected in myoblasts in growth medium and one day after shift to differentiation medium. RNA and protein samples were collected at 2 and 5 days of differentiation. After 2 days of treatment, dys-siRNA-treated cells (siDYS) showed a significant reduction of dystrophin mRNA (residual 61%) that, after 5 days, reached a residual value of 43% (Figure 2d) . Dystrophin decrease paralleled that of mRNA levels, even if at a lower extent (Figure 2e) , probably due to the well known long half-life of the dystrophin protein.
Notably, in RNAi-treated cells, both MHC and MCK accumulated at lower levels, with MHC being reduced to 42% of control levels at day 5 of differentiation; in contrast, early myogenic factors such as myogenin and myoD, were not affected by dystrophin reduction both in terms of protein and mRNA (Figure 2d, e) .
Altogether, these data support the hypothesis that dystrophin is a crucial myogenic factor regulating the progression from early to late phases of differentiation.
dystrophin rescue and mirnAs expression levels
In order to test whether the dystrophin protein produced in Δ44 myoblasts through skipping of exon 45, relocalizes and stabilizes nNOS, an immunofluorescence assay was performed with nNOS antibodies on myoblasts from: healthy control (CTRL), mockinfected (Δ44-PGK), and exon-skipping treated (Δ44#4) Δ44 cells. Figure 3a shows the correct localization of nNOS in control myotubes, revealed by well-defined increase in sarcolemmal labelling. Indeed, this striated staining is almost absent in Δ44-untreated myoblasts (Δ44-PGK), where only faint diffused cytoplasmic staining is visible. These results are in line with the well-known decrease and delocalization of nNOS in DMD patients. [8] [9] 46 Notably, when Δ44 cells were treated with exon skipping (Δ44#4), they displayed a well visible nNOS signal distributed along the fibers. These results indicate that the recovery of dystrophin synthesis allows the correct relocalization and stabilization of nNOS at the sarcolemma and that exons 44 and 45 are dispensable for this function.
It has been previously shown 15 that the DYS-nNOS pathway regulates, through the control of HDAC2 activity, the expression of a specific subset of miRNAs with specific function in muscle terminal differentiation (miR-1 and miR-133) or in muscle-degenerative processes such as fibrosis (miR-29 and miR-30). Conversely, miRNAs expressed in regenerating fibres, such as miR-31 and miR-206, were shown not to be controlled through this pathway. In order to test the dependence of these miRNAs from nNOS rescue in exonskipping treated Δ44 myoblasts, quantitative reverse transcriptase-PCR was performed on total RNA extracted from WT and Δ44 cells either mock infected (PGK) or treated with the different antisense constructs (#1 through #8). Figure 3b indicates that in Δ44 myoblasts miR-1 and miR-133 levels are strongly reduced with respect to healthy myoblasts (CTRL), in agreement with previous observation in Δ48-50 DMD myoblasts; 15 however, when exon skipping recovered dystrophin synthesis, increase in the levels of both miRNAs was obtained.
At difference with these miRNAs, miR-31 was upregulated in Δ44 cells and, upon dystrophin rescue, its expression remained high (Figure 3b) . Recently, it has been shown that Duchenne myoblasts contain reduced levels of linc-MD1, a long noncoding RNA required for muscle differentiation.
47 Figure 3b (lower panel) indicates that also Δ44 myoblasts have low levels of linc-MD1; notably, recovery of dystrophin synthesis induced increase in linc-MD1 levels. ChIP experiments on linc-MD1 promoter in mouse myoblasts indicated that this transcript is not under the control of HDAC2 (C. Pinnarò, personal communication, 5 December 2011); therefore, the increase of linc-MD1 upon dystrophin restoration does not directly depend on the DYS-nNOS pathway but it is likely due to an indirect effect on muscle differentiation, as previously discussed.
Altogether, these data confirm that the recovery of dystrophin in Δ44 cells restores nNOS sarcolemmal localization and in turn the biosynthesis of those miRNAs that depend on the DYS-nNOS pathway.
BMd
To further correlate the beneficial effects of dystrophin with the integrity of the DYS-nNOS pathway, we analyzed 14 biopsies from Becker patients carrying mutations differently affecting nNOS localization (representative examples are shown in Figure 4a and Supplementary Figure S2) . The expression of miR-1 and miR-29, previously shown to respond to the DYS-nNOS pathway, was analyzed from total RNA obtained from eight of such biopsies. Figure 4c shows that BMD samples lacking nNOS (BMD-5, -6, -7, and -8) display low levels of miR-1 and miR-29 if compared to BMD samples with reduced or normal levels of nNOS (BMD-1, -2, -3, and -4), confirming the direct correlation between nNOS and specific miRNA expression. Interestingly, in agreement with previous work, 19 biopsies lacking or having trace levels of nNOS corresponded to patients displaying an overall more severe clinical phenotype (Supplementary 48 This scale, that is routinely performed in the clinical follow-up of patients, consist in 20 consecutive motor activities each scored on a 3-point scale (2 to 0) and the total test score can range from 0 if the child cannot perform any of the items to 40 if all the items are fully achieved. The table indicates that in BMD patients the absence of nNOS correlates with a worse outcome (patients BMD-5, -6, -9, and -14) with the only exception of BMD-7 that show traces of nNOS, low miRNA levels but unaffected HFMS score.
Becker mutations completely lacking nNOS are those missing exons 45-47 and 45-49 as they more severely disrupt spectrin-like repeats 16 and 17. However, the finding that deletion 45-51 has visible levels of nNOS indicates that a direct relationship between primary sequence and protein activity cannot be simply made.
dIscussIon
Inducing exon skipping as a therapeutic approach of DMD relies on the concept of converting severe Duchenne phenotypes into the milder Becker ones. However, the latter display a large range of phenotypes likely reflecting the ability of shorter forms of dystrophin to accomplish only a subset of the different functions of the wild-type full-length protein. Multiple variables play a role in determining the efficiency of internally shortened dystrophins produced in Becker patients: these relate to structural properties of the residual dystrophin molecules as well as to their capacity to correctly assemble DAPC complexes and to relocalize nNOS. 19 Regarding the former, the spectrin-like repeat region is composed of 24 modular repeats found in the rod domain. While removing an integral repeat is mostly dispensable, deletions that affect the phasing of the repeats are associated with less stable and functional dystrophin molecules. 49 Concerning the role that different internal dystrophin deletions have on assembly of DAPC proteins, we have recently demonstrated that BMD dystrophins of patients with deletions located around exons 51 and 53 are more efficient in relocalising at the sarcolemma β-destroglycan and α-sarcoglycan compared to other deletions that remove spectrinlike repeats 16 and 17. 19 There is also a strong correlation between deletions of spectrin-like repeats 16 and 17 and ability to localize nNOS at the sarcolemma. 4, 5 These are crucial points when thinking of possible therapeutic benefits of exon skipping in different DMD mutations and suggest that dystrophin rescue should be tested together with correct recovery of the entire complex of proteins at the sarcolemma. We have recently shown that in DMD mutants lacking exons 48-50, further skipping of exon 51 is able to relocalize α-sarcoglycan and nNOS. 50 The relevance of nNOS was previously shown to rely on its ability to control gene expression through nitrosylation of HDAC2. The rescue of this pathway in dystrophic animals has been proved to ameliorate the dystrophic phenotype and to influence the expression of a specific subset of genes playing a crucial role in the control of muscle terminal differentiation and tissue homeostasis:
15 among them, those coding for relevant myogenic miRNAs (miR-1 and miR-133) and for species controlling fibro-adipocitic degeneration (miR-29 and miR-30). These data suggested that nNOS activity plays an important role in muscle homeostasis via its ability to directly regulate the expression of specific HDAC2 target genes and to have a positive effect on differentiation.
In this work, we produced antisense molecules, raised in the U1 snRNA backbone, able to induce effective skipping of exon 45 that is one of the most common, after exon 51, in terms of number of patients that can be cured (8.1% of known DMD mutations). We showed that rescue of dystrophin provided a considerable enhancement of differentiation in DMD myoblasts, well characterized for their delay in reaching a mature molecular and morphological phenotype. This evidence was further supported by experiments of RNAi against dystrophin in myoblasts from healthy individuals. In this case an evident delay in timing of myogenic markers synthesis was observed. Notably, while having such a clear effect on late differentiation markers, dystrophin did not show any specific effect on timing and levels of early myogenic markers such as Myogenin and MyoD.
Notably, the dystrophin protein, obtained through skipping of exon 45 in a Δ44 genetic background, produced efficient rescue of nNOS localization at the membrane, together with recovery of miR-1 and miR-133 expression, indicating the reactivation of the DYS-nNOS pathway. In line with the relevance of this pathway, nNOS analysis of different Becker individuals indicated that those lacking correct localization of the enzyme had a more severe clinical phenotype as well as reduction of those marker miRNAs depending on the DYS-nNOS pathway.
Altogether, these data demonstrate a crucial role of dystrophin in regulating the switch between early and late phases of muscle differentiation and point to the relevance of the DYS-nNOS pathway in DMD and BMD.
MAtErIAls And MEthods
Antisense clones construction. Clones U1-45 were obtained by inverse PCR on the construct pCCL-5′3′Esx RNA preparation and analysis. Cells were harvested with 1 ml of QIAzol Lysis Reagent (Qiagen) and biopsies were homogenized with a rotor-stator homogenizer in the presence of QIAzol Lysis Reagent (Qiagen). RNAs were extracted by miRNeasy (Qiagen), following manufacturer's specifications; concentration was assessed with Nanodrop ND-1000 Spectrophotometer (CELBIO; Pero, Milan, Italy). Quantitative reverse transcriptase-PCR were performed using miScript System (Qiagen).
Northern blot. Antisense expression was analyzed by northern blot as previously described 28 using the following probe: anti-45 (5′-CAGGAA CTCCAGG-3′).
Primary myoblasts cultures.
Cultures of primary myoblasts (WT-9808 and Δ44-9981 from the Telethon Neuromuscular Biobank) were first pre-plated in order to separate fibroblasts from the primary line, then seeded in Human skeletal muscle growth medium (PromoCell, Heidelberg, Germany) and grown in a humidified incubator, at 5% CO 2 and 37 °C.
Virus preparation and cell transduction. Viruses were prepared as described. 28 The day before transduction, myoblasts were seeded in growth medium, on 6-cm plates (at least two for each different virus), at a density of 5 × 10 5 cells per plate. The next day cells were infected once with lentiviruses and polybrene (4 mg/ml). Two days after infection, cells were induced to differentiate with human skeletal muscle differentiation medium (PromoCell). After 10 days of differentiation, cells were washed twice with complete phosphate-buffered saline (PBS) buffer (PromoCell) and collected with 300 ml of protein buffer (100 mmol/l Tris-HCl pH 7.4, 1 mmol/l EDTA, 2% SDS, 1× Complete EDTA-free Protease Inhibitor Cocktail (Roche, Applied Science, Mannheim, Germany) for protein extraction, or with 1 ml of QIAzol Lysis Reagent (Qiagen) for RNA extraction.
RT-PCR. Dystrophin mRNA was analyzed by RT-PCR (Access RT-PCR system-Promega, Madison, WI) on 200 ng of total RNA with oligos E42F (5′-GAAGACATGCCTTTGGAAATTTCT-3′) and E48R (5′-CTGAA CGTCAAATGGTCCTTC-3′). Four microlitres of the RT-PCR products were then used as template for a nested reaction performed with oligo E43F (5′-CTACAACAAAGCTCAGGTCG-3′) and E46R (5′-CTC TTTTCCAGGTTCAAGTGG-3′).
Antisense expression was analyzed by RT-PCR (SuperScript VILO cDNA Synthesis Kit; Invitrogen) on 50 ng of total RNA with oligos U1primer (5′-CAGGGGAAAGCGCGAACG-3′) and RT45 (5′-ATCC TGGAGTTCCTGTAA-3′). GAPDH was used as loading control (oligos: F 5′-GGAAGGTGAAGGTCGGAGTC-3′; R 5′-TTACCAGAGTTAAAA GCAGCCC-3′).
Ten microlitres of the reactions were run on a 2% agarose-ethidium bromide gel and signals were revealed on a UV transilluminator.
Western blot analysis. Western blot analyses were carried out as previously described. 28 Primary antibodies: anti-dystrophyn [NCL-DYS1; Novocastra Laboratories, New Castle upon Tyne, UK, 1:40 in 3% milk); anti-myosin (anti-MF-20, 1:20 in TBST), anti-MCK (sc-15161; Santa Cruz Biotechnology, Santa Cruz, CA) 1:500 in TBST]; anti-myogenin (MyoG sc-12732, 1:1,000 in TBST); anti-MyoD (DAKO, Glostrup, Denmark, 1:500 in 3% milk); anti-actinin (ACTN sc-15335, 1:1000 in TBST). Secondary antibodies: ImmunoPure Goat Anti-Rabbit IgG Peroxidase-Conjugated (Pierce, Rockford, IL, 1:5,000 in 5% milk); ImmunoPure®Goat Anti-Mouse IgG Peroxidase Conjugated (Pierce, 1:10,000 in 5% milk); donkey anti-goat IgG-HRP (sc-2020, diluted 1:5,000 in 3% milk).
RNA interference against dystrophin. The WT-9808 cell line, obtained from Telethon Genetic Biobank Network, was grown to 70% confluence on 6-cm plates in Dulbecco's modified Eagle's medium with 18% fetal bovine serum. Transfection was performed twice with 200 pmol of siRNA oligonucleotides targeting the dystrophin gene (Qiagen, target sequence: 5′-AATAACTTGCCATTTCTTTAT-3′) or 200 pmol of siRNA negative control using lipofectamine (Invitrogen) according to manufacturer's specification. After 18 hours, the medium was replaced. RNA and protein samples were collected after 2 and 5 days of differentiation.
Patients. Fourteen BMD patients, aged from 2 to 15 years, were assessed by physiotherapists to quantify muscular strength through Hammersmith motor ability score. 47 Skeletal muscle biopsies were obtained, with informed consent, from all BMD patients along with non-myopathic control. BMD-3, BMD-4, BMD-6, BMD-9, BMD-10, BMD-11, BMD-12, BMD-13, BMD-14, and control were obtained from Laboratory of Molecular Medicine, Department of Neuroscience, Bambino Gesù Children's Hospital, Rome whereas BMD-1, BMD-2, BMD-5, BMD-7, BMD-8, BMD-15 biopsies were obtained from Dubowitz Neuromuscular Centre, Institute of Child Health and Great Ormond Street Hospital, London.
Immunohistochemistry. Muscle biopsies were mounted in OCT medium. Serial 7-μm transverse cryosections were fixed for 15 minutes at 4 °C in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA), permeabilized with Triton 0.2%/1%BSA/PBS for 15 minutes and subsequently blocked in 10% goat serum/1%BSA/PBS for 1 hour at room temperature. Sections were incubated at 4 °C with primary antibodies diluted in 5% Goat Serum/PBS (incubation buffer) for 16 hours. After serial washes in 0.2% Triton /PBS, secondary antibodies (goat antiMouse IgG AlexaFluor 488; Invitrogen or Cy3 conjugated; Jackson ImmunoResearch, West Grove, PA) diluted 1:500 with incubation buffer were added for 1h at room temperature. The specificity of immunolabeling was verified in control samples prepared with the incubation buffer alone, followed by the second conjugated antibody. The sections were counterstained with 1.5 mg/ml 4′, 6-diamidino-2 phenylindole in Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA). Cultured cells were fixed in methanol/acetone for 20 minutes at -20 °C, subsequently air-dried and after brief rehydration with PBS processed for immunostaining with primary antibodies (diluted in 1% goat serum/ PBS) as described above.
Primary monoclonal antibodies used in this study were: diluted as follows: anti-Dystrophin NCL-DYS2, Novocastra Laboratories (diluted 1:12.5); anti-Nos-1 sc-55521 (diluted 1:50), anti-MHC from hybridoma supernatants.
Image acquisition and analysis. Immunostained cells and muscle sections were examined using a Zeiss AxioObserver A1 inverted fluorescence microscope equipped with Axiocam MRM R camera and Plan-Neofluar EC 10×/0.3 M27 and LD 40×/0.6 M27 objectives. The images were acquired with AxioVision Rel.4.8 imaging software.
Statistical analyses.
Each data shown in quantitative reverse transcriptase-PCR is the result of at least three independent experiments. Data are shown as mean ± SD. Unless specifically stated, statistical significance of differences between means was assessed by two-tailed t-test and a P < 0.05 was considered significant. Figure S1 . Analysis of muscle differentiation markers. Figure S2 . Dystrophin and nNOS localization in BMD biopsies. Table S1 . Description of antisense constructs. Table S2 . Clinical informations of BMD patients.
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